Visible node/edge number:
Node colors:
Node labels:

show label of nodes with degree >=

Node sizes:
Edge colors:
Edge widths factor:
Layout:

gravity >=

edgeLength =

GRN in network:

Notice: IE browser need to manually refresh (F5) this page after resetting the network.

This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.

"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.

miRNA-gene regulations

(Download full result)

Num microRNA           Gene miRNA log2FC miRNA pvalue Gene log2FC Gene pvalue Interaction Correlation beta Correlation P-value PMID Reported in cancer studies
1 hsa-miR-145-5p ADAM17 -3.56 0 1.46 0.00716 miRNAWalker2 validate -0.11 0.00806 25174729; 23441135 MicroRNA 145 inhibits cell proliferation by directly targeting ADAM17 in hepatocellular carcinoma; In the present study we showed that miR-145 is able to significantly reduce mRNA and protein expression levels of A disintegrin and metalloproteinase 17 ADAM17 in liver cancer cells SMMC-7721 BEL-7402 and Huh-7; Dual luciferase reporter assays confirmed that ADAM17 is a direct target of miR-145; In conclusion miR-145 inhibits liver cancer cell proliferation by directly targeting ADAM17;MicroRNA 145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients; Furthermore we show that ADAM17 negatively regulates miR-145 through tumor necrosis factor-α resulting in a reciprocal negative feedback loop; In this study the expression of ADAM17 and miR-145 correlated negatively in renal cancer tumor tissues and cell lines suggesting an important regulatory mechanism; Additionally we showed that the regulation of ADAM17 is partly involved in the effects of miR-145 on proliferation and migration whereas no involvement in chemosensitivity was observed; In summary miR-145 is downregulated in renal cancer patients which leads to the up-regulation of ADAM17 in renal cancer; Importantly miR-145 and ADAM17 are regulated in a reciprocal negative feedback loop
2 hsa-miR-21-3p CREBBP 3.5 0 -0.4 0.18067 MirTarget -0.14 0 NA
3 hsa-miR-590-3p CREBBP 2.35 0 -0.4 0.18067 PITA; miRanda; mirMAP; miRNATAP -0.1 0.00219 NA
4 hsa-miR-342-3p CTBP2 1.31 0.02072 -0.53 0.12195 MirTarget; PITA; miRanda; miRNATAP -0.13 0.00023 NA
5 hsa-miR-34a-5p DLL1 0.83 0.04775 -1.05 0.27477 miRNAWalker2 validate; miRTarBase; miRNATAP -0.37 0.0045 22438124 Delta tocotrienol suppresses Notch 1 pathway by upregulating miR 34a in nonsmall cell lung cancer cells
6 hsa-miR-429 DLL1 6.4 0 -1.05 0.27477 miRanda; miRNATAP -0.18 0.00942 NA
7 hsa-let-7a-3p DLL4 0.83 0.04681 -2.41 4.0E-5 miRNATAP -0.27 0.00085 NA
8 hsa-let-7b-3p DLL4 0.59 0.20051 -2.41 4.0E-5 miRNATAP -0.39 0 NA
9 hsa-miR-15b-5p DLL4 3.32 0 -2.41 4.0E-5 miRNATAP -0.32 0 NA
10 hsa-miR-16-5p DLL4 2.94 0 -2.41 4.0E-5 miRNATAP -0.34 0 NA
11 hsa-miR-429 DLL4 6.4 0 -2.41 4.0E-5 miRanda -0.18 2.0E-5 NA
12 hsa-miR-3199 DTX1 -0.38 0.52979 -0.06 0.93478 miRNATAP -0.24 0.00051 NA
13 hsa-miR-421 DTX1 1.98 0.00092 -0.06 0.93478 PITA; miRanda; miRNATAP -0.19 0.00671 NA
14 hsa-let-7e-5p DTX2 -0.11 0.81474 1.72 0.00044 miRNATAP -0.2 0.00084 NA
15 hsa-miR-92b-3p DTX2 1.69 0.01035 1.72 0.00044 miRNATAP -0.21 0 NA
16 hsa-miR-185-5p DTX3 2.47 0 -1.87 0.00194 MirTarget -0.26 0.00051 NA
17 hsa-miR-182-5p DTX3L 5.87 0 1.5 0.00034 mirMAP -0.12 8.0E-5 NA
18 hsa-miR-186-5p DTX3L 0.45 0.18545 1.5 0.00034 MirTarget -0.22 0.00252 NA
19 hsa-miR-493-5p DTX3L 0.17 0.8342 1.5 0.00034 MirTarget -0.12 3.0E-5 NA
20 hsa-miR-495-3p DTX3L -1.28 0.09795 1.5 0.00034 mirMAP -0.13 4.0E-5 NA
21 hsa-let-7a-5p DTX4 0.15 0.64531 0.52 0.53581 TargetScan; miRNATAP -0.59 7.0E-5 NA
22 hsa-let-7b-5p DTX4 -0.19 0.65188 0.52 0.53581 miRNATAP -0.34 0.00319 NA
23 hsa-let-7f-5p DTX4 0.97 0.02403 0.52 0.53581 miRNATAP -0.29 0.00832 NA
24 hsa-miR-125b-5p DTX4 -2.01 0.00516 0.52 0.53581 mirMAP; miRNATAP -0.23 0.00045 NA
25 hsa-miR-27a-3p DTX4 1.76 0.00022 0.52 0.53581 miRNATAP -0.28 0.00489 NA
26 hsa-miR-27b-3p DTX4 -0.09 0.85847 0.52 0.53581 miRNATAP -0.38 3.0E-5 NA
27 hsa-miR-10a-5p DVL1 -0.48 0.59461 0.09 0.80261 miRNAWalker2 validate -0.11 0 NA
28 hsa-miR-125a-5p DVL3 -1.32 0.00714 0.71 0.04418 PITA -0.11 0.0051 NA
29 hsa-miR-146b-3p DVL3 1.35 0.00936 0.71 0.04418 MirTarget -0.15 7.0E-5 NA
30 hsa-miR-29b-2-5p DVL3 -0.6 0.18954 0.71 0.04418 MirTarget -0.12 0.00737 NA
31 hsa-miR-30a-3p DVL3 -1.22 0.16757 0.71 0.04418 MirTarget -0.12 0 NA
32 hsa-miR-148a-3p EP300 1.1 0.05204 0.22 0.57893 miRNATAP -0.1 0.00975 NA
33 hsa-miR-30c-5p EP300 0.39 0.34861 0.22 0.57893 miRNAWalker2 validate -0.19 0.0009 NA
34 hsa-miR-339-5p EP300 1.23 0.03075 0.22 0.57893 miRanda -0.2 0 NA
35 hsa-miR-342-3p EP300 1.31 0.02072 0.22 0.57893 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00407 NA
36 hsa-miR-374b-5p EP300 -0.11 0.76489 0.22 0.57893 mirMAP; miRNATAP -0.16 0.00856 NA
37 hsa-miR-590-3p EP300 2.35 0 0.22 0.57893 MirTarget; PITA; miRanda; mirMAP; miRNATAP -0.14 0.00229 NA
38 hsa-miR-146b-5p HDAC2 1.88 0.00074 0.4 0.22265 mirMAP -0.12 0.00029 NA
39 hsa-miR-324-5p HES1 1.31 0.01168 0.73 0.15297 miRanda -0.15 0.00785 NA
40 hsa-miR-128-3p JAG1 1.36 0.00408 0.3 0.66716 MirTarget -0.24 0.00447 NA
41 hsa-miR-129-5p JAG1 -2.67 0.00696 0.3 0.66716 PITA; miRanda; miRNATAP -0.11 0.00769 NA
42 hsa-miR-141-3p JAG1 7.3 0 0.3 0.66716 TargetScan; miRNATAP -0.25 0 NA
43 hsa-miR-186-5p JAG1 0.45 0.18545 0.3 0.66716 MirTarget; miRNATAP -0.48 6.0E-5 NA
44 hsa-miR-200a-3p JAG1 6.34 0 0.3 0.66716 miRNATAP -0.26 0 NA
45 hsa-miR-200c-3p JAG1 6.47 0 0.3 0.66716 miRNAWalker2 validate -0.23 0.00015 NA
46 hsa-miR-26b-3p JAG1 0.99 0.03514 0.3 0.66716 miRNATAP -0.27 0.00177 NA
47 hsa-miR-335-5p JAG1 0.17 0.8039 0.3 0.66716 miRNATAP -0.25 2.0E-5 NA
48 hsa-miR-34a-5p JAG1 0.83 0.04775 0.3 0.66716 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.4 3.0E-5 NA
49 hsa-miR-361-3p JAG1 0.81 0.04185 0.3 0.66716 miRNATAP -0.34 0.00076 NA
50 hsa-miR-375 JAG1 3.38 0.04499 0.3 0.66716 miRNAWalker2 validate -0.19 0 NA
51 hsa-miR-429 JAG1 6.4 0 0.3 0.66716 miRanda -0.2 0.00011 NA
52 hsa-miR-628-5p JAG1 1.05 0.02524 0.3 0.66716 MirTarget; PITA; miRNATAP -0.33 0.00013 NA
53 hsa-miR-93-3p JAG1 2.63 0 0.3 0.66716 MirTarget; miRNATAP -0.25 0.00145 NA
54 hsa-miR-140-3p JAG2 -1.98 0 0.72 0.28163 miRNATAP -0.29 0.00501 NA
55 hsa-miR-106b-5p KAT2B 2.81 0 -1.07 0.03591 miRNAWalker2 validate; miRTarBase; MirTarget -0.28 1.0E-5 NA
56 hsa-miR-125a-3p KAT2B -0.07 0.92074 -1.07 0.03591 miRanda -0.16 3.0E-5 NA
57 hsa-miR-17-5p KAT2B 2.33 2.0E-5 -1.07 0.03591 MirTarget; TargetScan -0.22 3.0E-5 23095762 miR 17 5p targets the p300/CBP associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells; Targeting of PCAF by miR-17-5p was evaluated using the luciferase reporter assay; Expression of PCAF in PCa cells was associated with the downregulation of miR-17-5p; Targeting of the 3'-untranslated region of PCAF mRNA by miR-17-5p caused translational suppression and RNA degradation and consequently modulation of AR transcriptional activity in PCa cells; PCAF is upregulated in cultured PCa cells and upregulation of PCAF is associated with the downregulation of miR-17-5p; Targeting of PCAF by miR-17-5p modulates AR transcriptional activity and cell growth in cultured PCa cells
58 hsa-miR-181b-5p KAT2B 1.11 0.02734 -1.07 0.03591 miRNAWalker2 validate; miRTarBase; MirTarget -0.17 0.00245 NA
59 hsa-miR-181d-5p KAT2B -0.53 0.32526 -1.07 0.03591 MirTarget -0.17 0.0017 NA
60 hsa-miR-19b-3p KAT2B 1.68 0.00086 -1.07 0.03591 miRNAWalker2 validate -0.2 0.0005 NA
61 hsa-miR-20a-3p KAT2B 1.99 0.00062 -1.07 0.03591 MirTarget -0.28 0 NA
62 hsa-miR-25-3p KAT2B 1.13 0.00311 -1.07 0.03591 miRNAWalker2 validate; miRTarBase; MirTarget -0.28 0.00021 NA
63 hsa-miR-26b-5p KAT2B 0.31 0.46163 -1.07 0.03591 miRNAWalker2 validate -0.21 0.00228 NA
64 hsa-miR-32-5p KAT2B 2.93 0 -1.07 0.03591 miRNAWalker2 validate; miRTarBase; MirTarget -0.17 0.00439 NA
65 hsa-miR-330-3p KAT2B 2.49 0.00013 -1.07 0.03591 MirTarget -0.13 0.00461 NA
66 hsa-miR-590-3p KAT2B 2.35 0 -1.07 0.03591 MirTarget; miRanda; mirMAP; miRNATAP -0.2 0.0004 NA
67 hsa-miR-590-5p KAT2B 1.51 0.00239 -1.07 0.03591 miRanda -0.28 0 NA
68 hsa-miR-92a-3p KAT2B 1.88 1.0E-5 -1.07 0.03591 miRNAWalker2 validate; MirTarget -0.33 0 NA
69 hsa-miR-92b-3p KAT2B 1.69 0.01035 -1.07 0.03591 MirTarget -0.17 6.0E-5 NA
70 hsa-miR-93-5p KAT2B 2.66 0 -1.07 0.03591 miRNAWalker2 validate; miRTarBase; MirTarget -0.2 0.00062 NA
71 hsa-miR-590-3p MAML2 2.35 0 -0.41 0.60226 mirMAP -0.33 0.00019 NA
72 hsa-miR-664a-3p MAML2 0.25 0.56171 -0.41 0.60226 mirMAP -0.31 0.00284 NA
73 hsa-miR-125a-3p MAML3 -0.07 0.92074 -1.6 0.02486 miRanda -0.25 0 NA
74 hsa-miR-326 MAML3 1.77 0.03673 -1.6 0.02486 miRanda -0.14 0.0035 NA
75 hsa-miR-330-5p MAML3 2.25 0.00028 -1.6 0.02486 miRanda -0.29 1.0E-5 NA
76 hsa-miR-339-5p MAML3 1.23 0.03075 -1.6 0.02486 miRanda -0.37 0 NA
77 hsa-miR-590-3p MAML3 2.35 0 -1.6 0.02486 miRanda -0.33 3.0E-5 NA
78 hsa-miR-219a-5p MFNG 0.99 0.12552 -2.29 0.00025 MirTarget -0.2 0.00026 NA
79 hsa-miR-3607-3p NCOR2 1.38 0.02401 -0.15 0.63362 miRNATAP -0.13 0 NA
80 hsa-miR-129-5p NOTCH1 -2.67 0.00696 0.77 0.22007 miRNAWalker2 validate -0.11 0.00232 NA
81 hsa-miR-200b-3p NOTCH1 5.56 0 0.77 0.22007 MirTarget; TargetScan -0.13 0.00897 26012256; 23430952 Nobiletin inhibited hypoxia induced epithelial mesenchymal transition of lung cancer cells by inactivating of Notch 1 signaling and switching on miR 200b; Our findings suggest that downregulation of Notch-1 and reexpression of miR-200b by nobiletin might be a novel remedy for the therapy of lung cancer;We also found that reexpression of miR-34a and miR-200b by transfection led to reduced expression of Notch-1 resulting in the inhibition of osteosarcoma cell proliferation invasion and angiogenesis
82 hsa-miR-28-5p NOTCH1 -0.82 0.02212 0.77 0.22007 miRanda -0.3 0.00345 NA
83 hsa-miR-30a-5p NOTCH1 -0.77 0.32049 0.77 0.22007 miRNAWalker2 validate; miRTarBase; miRNATAP -0.2 1.0E-5 NA
84 hsa-miR-326 NOTCH1 1.77 0.03673 0.77 0.22007 miRNAWalker2 validate; miRTarBase -0.13 0.00292 NA
85 hsa-miR-34a-5p NOTCH1 0.83 0.04775 0.77 0.22007 miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP -0.23 0.00673 20351093; 22438124; 23140286; 24349627; 24565525; 25783790; 27082152; 23642368; 22347519; 23430952; 23902763; 21743299; 22992310; 23145211; 25623761; 23085450 MicroRNA 34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells; Computational miRNA target prediction suggested that Notch1 and Jagged1 were targets of miR-34a; By using functional assays miR-34a was demonstrated to bind to the 3' untranslated regions of Notch1 and Jagged1; Forced expression of miR-34a altered the expression of Notch1 and Jagged1 protein as well as Notch signaling as shown by the response of Hairy Enhancer of Split-1 protein to these treatments using western blot analysis;Delta tocotrienol suppresses Notch 1 pathway by upregulating miR 34a in nonsmall cell lung cancer cells; In our study using miRNA microarray we observed that downregulation of the Notch-1 pathway by delta-tocotrienol correlated with upregulation of miR-34a in nonsmall cell lung cancer cells NSCLC;We found that Re-expression forced expression of miR-34a inhibits cell growth and induces apoptosis with concomitant down-regulation of Notch-1 signaling pathway one of the target of miR-34a; Moreover treatment of PC cells with a natural compound genistein led to the up-regulation of miR-34a resulting in the down-regulation of Notch-1 which was correlated with inhibition of cell growth and induction of apoptosis;Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed reexpression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens;In addition intracellular restoration of miR-34a inhibited breast cancer cell migration via targeting Notch-1 signaling;MicroRNA 34a suppresses the breast cancer stem cell like characteristics by downregulating Notch1 pathway; In this study we verified that miR-34a directly and functionally targeted Notch1 in MCF-7 cells; We reported that miR-34a negatively regulated cell proliferation migration and invasion and breast cancer stem cell propagation by downregulating Notch1; The expression of miR-34a was negatively correlated with tumor stages metastasis and Notch1 expression in breast cancer tissues; Furthermore overexpression of miR-34a increased chemosensitivity of breast cancer cells to paclitaxel PTX by downregulating the Notch1 pathway; Taken together our results indicate that miR-34a inhibited breast cancer stemness and increased the chemosensitivity to PTX partially by downregulating the Notch1 pathway suggesting that miR-34a/Notch1 play an important role in regulating breast cancer stem cells;We showed that miR-34a as a tumor suppressor could separately reduce the stemness of BCSCs and activate the cytotoxic susceptibility of BCSCs to natural killer NK cells in vitro via down regulating the expression of Notch1 signaling molecules;Mechanistically miR-34a sequesters Notch1 mRNA to generate a sharp threshold response where a bimodal Notch signal specifies the choice between self-renewal and differentiation;Most importantly BR-DIM intervention in PCa patients prior to radical prostatectomy showed re-expression of miR-34a which was consistent with decreased expression of AR PSA and Notch-1 in PCa tissue specimens;We also found that reexpression of miR-34a and miR-200b by transfection led to reduced expression of Notch-1 resulting in the inhibition of osteosarcoma cell proliferation invasion and angiogenesis;Rhamnetin and cirsiliol induce radiosensitization and inhibition of epithelial mesenchymal transition EMT by miR 34a mediated suppression of Notch 1 expression in non small cell lung cancer cell lines; Indeed rhamnetin and cirsiliol increased the expression of tumor-suppressive microRNA miR-34a in a p53-dependent manner leading to inhibition of Notch-1 expression;MicroRNA 34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme; Also we identified notch1 as a direct target gene of miR-34a; Knockdown of notch1 showed similar cellular functions as overexpression of miR-34a both in vitro and in vivo; Collectively our findings show that miR-34a is downregulated in GBM cells and inhibits GBM growth by targeting notch1;The re-expression of miR-34 led to a marked reduction in the expression of its target gene Notch-1;Inactivation of AR and Notch 1 signaling by miR 34a attenuates prostate cancer aggressiveness; We found that over-expression of miR-34a led to reduced expression of AR PSA and Notch-1; These findings suggest that the loss of miR-34a is directly linked with up-regulation of AR and Notch-1 both of which are highly expressed in PCa and thus finding innovative approaches by which miR-34a expression could be up-regulated will have a huge impact on the treatment of PCa especially for the treatment of mCRPC;miR 34a may regulate sensitivity of breast cancer cells to adriamycin via targeting Notch1; To explore the influence of miR-34a on Notch1 expression in breast cancer cells and to explore the role of miR-34a in the sensitivity of breast cancer cells to Adriamycin ADR; The expression levels of Notch1 mRNA and protein in MCF-7/ADR cells transfected with miR-34a mimics were significantly up-regulated; On the contrary the expressions of Notch1 mRNA and protein in MCF-7 cells transfected with miR-34a inhibitor were down-regulated; miR-34a negatively regulates the expression of Notch1 at both mRNA and protein levels;MicroRNA 34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1; The association of miR-34a and Notch1 was analyzed by dual-luciferase reporter assay and Notch1-siRNA technology; Real-time PCR assay was performed to test the expression of miR-34a and Notch1 in 38 selective breast cancer tissue samples; MiR-34a mimic could inhibit the luciferase activity of the construct containing wild-type 3' UTR of Notch1 in MCF-7/ADR cells; Further there was an inverse association between Notch1 and miR-34a expression in breast cancer; Dysregulation of miR-34a plays critical roles in the acquired ADR resistance of breast cancer at least in part via targeting Notch1
86 hsa-miR-429 NOTCH1 6.4 0 0.77 0.22007 MirTarget; PITA; miRanda; miRNATAP -0.12 0.00731 NA
87 hsa-miR-582-5p NOTCH1 0.69 0.44776 0.77 0.22007 PITA; miRNATAP -0.11 0.00735 NA
88 hsa-miR-92b-3p NOTCH1 1.69 0.01035 0.77 0.22007 miRNATAP -0.28 0 NA
89 hsa-miR-125a-5p NOTCH2 -1.32 0.00714 -0.18 0.70154 miRanda -0.19 0.00041 NA
90 hsa-miR-1287-5p NOTCH2 0.02 0.97561 -0.18 0.70154 MirTarget -0.19 0 NA
91 hsa-miR-130a-5p NOTCH2 1.58 0.02435 -0.18 0.70154 mirMAP -0.13 0.00065 NA
92 hsa-miR-15b-5p NOTCH2 3.32 0 -0.18 0.70154 MirTarget -0.16 0.00459 NA
93 hsa-miR-16-5p NOTCH2 2.94 0 -0.18 0.70154 miRNAWalker2 validate; MirTarget -0.2 0.00043 NA
94 hsa-miR-17-5p NOTCH2 2.33 2.0E-5 -0.18 0.70154 miRNAWalker2 validate -0.17 0.0005 NA
95 hsa-miR-181b-5p NOTCH2 1.11 0.02734 -0.18 0.70154 MirTarget; mirMAP -0.16 0.00244 NA
96 hsa-miR-18a-3p NOTCH2 3.65 0 -0.18 0.70154 MirTarget -0.13 0.00033 NA
97 hsa-miR-25-3p NOTCH2 1.13 0.00311 -0.18 0.70154 miRNAWalker2 validate -0.23 0.00142 NA
98 hsa-miR-29b-3p NOTCH2 0.67 0.23406 -0.18 0.70154 MirTarget -0.13 0.00738 NA
99 hsa-miR-30b-5p NOTCH2 0.02 0.95322 -0.18 0.70154 mirMAP -0.34 0 NA
100 hsa-miR-423-5p NOTCH2 0.23 0.56535 -0.18 0.70154 MirTarget -0.22 0.00133 NA
101 hsa-miR-590-3p NOTCH2 2.35 0 -0.18 0.70154 miRanda -0.18 0.00072 NA
102 hsa-miR-590-5p NOTCH2 1.51 0.00239 -0.18 0.70154 miRanda -0.17 0.00163 NA
103 hsa-miR-7-1-3p NOTCH2 1.43 0.00471 -0.18 0.70154 MirTarget; mirMAP -0.19 0.00039 NA
104 hsa-miR-92a-3p NOTCH2 1.88 1.0E-5 -0.18 0.70154 miRNAWalker2 validate -0.2 0.00149 NA
105 hsa-miR-200a-3p NOTCH3 6.34 0 0.62 0.39638 mirMAP -0.22 1.0E-5 NA
106 hsa-miR-335-5p NOTCH3 0.17 0.8039 0.62 0.39638 miRNAWalker2 validate -0.3 0 NA
107 hsa-miR-491-5p NOTCH3 0.57 0.31331 0.62 0.39638 MirTarget; miRanda -0.25 0.00074 NA
108 hsa-miR-18a-3p NOTCH4 3.65 0 -2.46 1.0E-5 miRNAWalker2 validate -0.12 0.00454 NA
109 hsa-miR-193a-3p NOTCH4 0.65 0.20713 -2.46 1.0E-5 miRanda -0.22 0.0004 NA
110 hsa-miR-330-5p NOTCH4 2.25 0.00028 -2.46 1.0E-5 miRanda -0.25 0 NA
111 hsa-miR-429 NOTCH4 6.4 0 -2.46 1.0E-5 miRNATAP -0.15 0.00014 NA
112 hsa-miR-374b-5p NUMB -0.11 0.76489 -0.13 0.60814 miRNATAP -0.13 0.00087 NA
113 hsa-miR-194-3p NUMBL 1.92 0.10538 -1.5 0.00091 MirTarget -0.14 0 NA
114 hsa-miR-186-5p PSEN1 0.45 0.18545 0.37 0.17061 mirMAP -0.19 5.0E-5 NA
115 hsa-miR-429 PSEN2 6.4 0 -1.01 0.07976 miRNATAP -0.12 0.00463 NA

Over-represented Gene Ontology Biological Process

NumGOOverlapSizeP ValueAdj. P Value
1 NOTCH SIGNALING PATHWAY 21 114 1.456e-41 6.776e-38
2 NOTCH RECEPTOR PROCESSING 9 16 1.154e-22 2.686e-19
3 REGULATION OF NOTCH SIGNALING PATHWAY 9 67 4.111e-16 6.377e-13
4 REGULATION OF NERVOUS SYSTEM DEVELOPMENT 15 750 3.264e-14 3.797e-11
5 POSITIVE REGULATION OF NOTCH SIGNALING PATHWAY 7 34 4.201e-14 3.909e-11
6 CELL FATE COMMITMENT 10 227 7.166e-13 5.557e-10
7 POSITIVE REGULATION OF GENE EXPRESSION 18 1733 2.189e-12 1.455e-09
8 REGULATION OF CELL DEVELOPMENT 14 836 3.482e-12 2.025e-09
9 MORPHOGENESIS OF AN EPITHELIUM 11 400 6.939e-12 3.587e-09
10 REGULATION OF NEURON DIFFERENTIATION 12 554 9.956e-12 4.633e-09
11 EPITHELIUM DEVELOPMENT 14 945 1.802e-11 7.622e-09
12 TRANSCRIPTION INITIATION FROM RNA POLYMERASE II PROMOTER 8 153 4.951e-11 1.92e-08
13 POSITIVE REGULATION OF BIOSYNTHETIC PROCESS 17 1805 6.214e-11 2.224e-08
14 TISSUE MORPHOGENESIS 11 533 1.501e-10 4.99e-08
15 TUBE DEVELOPMENT 11 552 2.178e-10 6.755e-08
16 REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT 16 1672 2.491e-10 7.012e-08
17 NEUROGENESIS 15 1402 2.562e-10 7.012e-08
18 NEGATIVE REGULATION OF NEURON DIFFERENTIATION 8 191 2.921e-10 7.55e-08
19 IMMUNE SYSTEM DEVELOPMENT 11 582 3.815e-10 9.342e-08
20 DNA TEMPLATED TRANSCRIPTION INITIATION 8 202 4.559e-10 1.061e-07
21 HEART MORPHOGENESIS 8 212 6.689e-10 1.153e-07
22 REGULATION OF CELL DIFFERENTIATION 15 1492 6.116e-10 1.153e-07
23 POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 13 1004 6.425e-10 1.153e-07
24 NEURON FATE COMMITMENT 6 67 6.265e-10 1.153e-07
25 CARDIOVASCULAR SYSTEM DEVELOPMENT 12 788 5.794e-10 1.153e-07
26 CIRCULATORY SYSTEM DEVELOPMENT 12 788 5.794e-10 1.153e-07
27 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 16 1784 6.519e-10 1.153e-07
28 TISSUE DEVELOPMENT 15 1518 7.781e-10 1.293e-07
29 HEART DEVELOPMENT 10 466 8.478e-10 1.36e-07
30 POSITIVE REGULATION OF CELL COMMUNICATION 15 1532 8.842e-10 1.371e-07
31 ORGAN MORPHOGENESIS 12 841 1.215e-09 1.824e-07
32 NEURON DIFFERENTIATION 12 874 1.88e-09 2.734e-07
33 POSITIVE REGULATION OF RESPONSE TO STIMULUS 16 1929 2.061e-09 2.906e-07
34 EMBRYO DEVELOPMENT 12 894 2.429e-09 3.324e-07
35 EMBRYONIC MORPHOGENESIS 10 539 3.441e-09 4.575e-07
36 NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 8 262 3.555e-09 4.595e-07
37 TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 11 724 3.779e-09 4.753e-07
38 MORPHOGENESIS OF AN EPITHELIAL SHEET 5 43 4.947e-09 5.902e-07
39 CELL FATE DETERMINATION 5 43 4.947e-09 5.902e-07
40 ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS 12 957 5.234e-09 6.088e-07
41 EPITHELIAL CELL FATE COMMITMENT 4 15 5.549e-09 6.297e-07
42 REGULATION OF BINDING 8 283 6.505e-09 7.207e-07
43 CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT 4 16 7.391e-09 7.998e-07
44 LEUKOCYTE DIFFERENTIATION 8 292 8.309e-09 8.786e-07
45 CARDIAC CHAMBER MORPHOGENESIS 6 104 9.169e-09 9.481e-07
46 CARDIAC SEPTUM MORPHOGENESIS 5 49 9.738e-09 9.85e-07
47 POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT 9 437 9.959e-09 9.859e-07
48 NEGATIVE REGULATION OF CELL DEVELOPMENT 8 303 1.109e-08 1.075e-06
49 ARTERY MORPHOGENESIS 5 51 1.197e-08 1.137e-06
50 EAR DEVELOPMENT 7 195 1.266e-08 1.178e-06
51 NEURONAL STEM CELL POPULATION MAINTENANCE 4 19 1.569e-08 1.432e-06
52 TUBE MORPHOGENESIS 8 323 1.823e-08 1.631e-06
53 POSITIVE REGULATION OF CELL DEVELOPMENT 9 472 1.938e-08 1.702e-06
54 LYMPHOCYTE DIFFERENTIATION 7 209 2.043e-08 1.761e-06
55 LYMPHOCYTE ACTIVATION 8 342 2.841e-08 2.36e-06
56 SENSORY ORGAN DEVELOPMENT 9 493 2.82e-08 2.36e-06
57 POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 13 1395 3.413e-08 2.786e-06
58 CARDIAC CHAMBER DEVELOPMENT 6 144 6.461e-08 5.184e-06
59 NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER 10 740 6.945e-08 5.477e-06
60 AUDITORY RECEPTOR CELL DIFFERENTIATION 4 28 8.212e-08 6.368e-06
61 ARTERY DEVELOPMENT 5 75 8.578e-08 6.543e-06
62 LEUKOCYTE ACTIVATION 8 414 1.237e-07 9.286e-06
63 REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS 11 1021 1.297e-07 9.578e-06
64 PATTERN SPECIFICATION PROCESS 8 418 1.332e-07 9.683e-06
65 NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS 10 801 1.455e-07 1.042e-05
66 CARDIAC SEPTUM DEVELOPMENT 5 85 1.613e-07 1.137e-05
67 NEGATIVE REGULATION OF CELL DIFFERENTIATION 9 609 1.713e-07 1.189e-05
68 POSITIVE REGULATION OF CELL DIFFERENTIATION 10 823 1.872e-07 1.281e-05
69 B CELL DIFFERENTIATION 5 89 2.033e-07 1.371e-05
70 HAIR CELL DIFFERENTIATION 4 35 2.085e-07 1.386e-05
71 ENDOTHELIUM DEVELOPMENT 5 90 2.15e-07 1.409e-05
72 NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION 4 37 2.624e-07 1.696e-05
73 VASCULATURE DEVELOPMENT 8 469 3.204e-07 2.042e-05
74 POSITIVE REGULATION OF DEVELOPMENTAL PROCESS 11 1142 4.005e-07 2.518e-05
75 CELL DEVELOPMENT 12 1426 4.258e-07 2.642e-05
76 EPITHELIAL CELL DIFFERENTIATION 8 495 4.822e-07 2.952e-05
77 COLUMNAR CUBOIDAL EPITHELIAL CELL DIFFERENTIATION 5 111 6.135e-07 3.707e-05
78 REGULATION OF TIMING OF CELL DIFFERENTIATION 3 12 6.639e-07 3.91e-05
79 REGULATION OF DEVELOPMENT HETEROCHRONIC 3 12 6.639e-07 3.91e-05
80 REGULATION OF EMBRYONIC DEVELOPMENT 5 114 7.005e-07 4.075e-05
81 REGULATION OF CELL PROLIFERATION 12 1496 7.13e-07 4.096e-05
82 NEPHRON DEVELOPMENT 5 115 7.316e-07 4.152e-05
83 GLOMERULUS DEVELOPMENT 4 49 8.314e-07 4.661e-05
84 NEGATIVE REGULATION OF EPIDERMAL CELL DIFFERENTIATION 3 13 8.622e-07 4.72e-05
85 MATURE B CELL DIFFERENTIATION INVOLVED IN IMMUNE RESPONSE 3 13 8.622e-07 4.72e-05
86 BLOOD VESSEL MORPHOGENESIS 7 364 8.863e-07 4.795e-05
87 REGULATION OF EPITHELIAL CELL DIFFERENTIATION 5 122 9.809e-07 5.187e-05
88 MECHANORECEPTOR DIFFERENTIATION 4 51 9.785e-07 5.187e-05
89 EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING 8 554 1.126e-06 5.888e-05
90 POSITIVE REGULATION OF BINDING 5 127 1.197e-06 6.188e-05
91 N TERMINAL PROTEIN AMINO ACID ACETYLATION 3 15 1.369e-06 6.924e-05
92 CELL ACTIVATION 8 568 1.358e-06 6.924e-05
93 B CELL ACTIVATION 5 132 1.449e-06 7.171e-05
94 MAINTENANCE OF CELL NUMBER 5 132 1.449e-06 7.171e-05
95 NEGATIVE REGULATION OF EPIDERMIS DEVELOPMENT 3 16 1.683e-06 8.244e-05
96 EPIDERMIS DEVELOPMENT 6 253 1.778e-06 8.616e-05
97 IMMUNE SYSTEM PROCESS 13 1984 2.049e-06 9.727e-05
98 MATURE B CELL DIFFERENTIATION 3 17 2.042e-06 9.727e-05
99 EPIDERMAL CELL DIFFERENTIATION 5 142 2.077e-06 9.76e-05
100 EMBRYONIC HEART TUBE MORPHOGENESIS 4 62 2.159e-06 0.0001005
101 NEUROEPITHELIAL CELL DIFFERENTIATION 4 63 2.303e-06 0.0001061
102 NEURAL TUBE DEVELOPMENT 5 149 2.631e-06 0.00012
103 KIDNEY VASCULATURE DEVELOPMENT 3 19 2.904e-06 0.0001299
104 RENAL SYSTEM VASCULATURE DEVELOPMENT 3 19 2.904e-06 0.0001299
105 EMBRYONIC ORGAN MORPHOGENESIS 6 279 3.13e-06 0.0001387
106 ENDOTHELIAL CELL DIFFERENTIATION 4 72 3.941e-06 0.000173
107 EMBRYONIC HEART TUBE DEVELOPMENT 4 73 4.165e-06 0.0001795
108 ANGIOGENESIS 6 293 4.149e-06 0.0001795
109 MEMBRANE PROTEIN ECTODOMAIN PROTEOLYSIS 3 22 4.601e-06 0.0001929
110 SOMATIC STEM CELL DIVISION 3 22 4.601e-06 0.0001929
111 AORTA MORPHOGENESIS 3 22 4.601e-06 0.0001929
112 RENAL TUBULE DEVELOPMENT 4 78 5.431e-06 0.0002256
113 RESPONSE TO OXYGEN LEVELS 6 311 5.841e-06 0.0002384
114 REGIONALIZATION 6 311 5.841e-06 0.0002384
115 N TERMINAL PROTEIN AMINO ACID MODIFICATION 3 26 7.736e-06 0.000313
116 CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 7 513 8.552e-06 0.000343
117 NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS 9 983 9.057e-06 0.0003602
118 ANTERIOR POSTERIOR PATTERN SPECIFICATION 5 194 9.543e-06 0.0003763
119 REGULATION OF SPROUTING ANGIOGENESIS 3 28 9.727e-06 0.0003804
120 STEM CELL DIVISION 3 29 1.084e-05 0.0004168
121 REGULATION OF OLIGODENDROCYTE DIFFERENTIATION 3 29 1.084e-05 0.0004168
122 NEPHRON EPITHELIUM DEVELOPMENT 4 93 1.094e-05 0.0004174
123 FOREBRAIN DEVELOPMENT 6 357 1.282e-05 0.000485
124 CARDIAC ATRIUM DEVELOPMENT 3 31 1.331e-05 0.0004993
125 LYMPHOCYTE ACTIVATION INVOLVED IN IMMUNE RESPONSE 4 98 1.347e-05 0.0005014
126 SKIN DEVELOPMENT 5 211 1.433e-05 0.0005291
127 POSITIVE REGULATION OF GLIAL CELL DIFFERENTIATION 3 32 1.467e-05 0.0005332
128 REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER IN RESPONSE TO HYPOXIA 3 32 1.467e-05 0.0005332
129 HEART VALVE DEVELOPMENT 3 34 1.766e-05 0.000637
130 CARDIAC VENTRICLE DEVELOPMENT 4 106 1.837e-05 0.0006575
131 MEMBRANE PROTEIN PROTEOLYSIS 3 35 1.93e-05 0.0006802
132 B CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE 3 35 1.93e-05 0.0006802
133 CELL DIFFERENTIATION INVOLVED IN KIDNEY DEVELOPMENT 3 36 2.103e-05 0.0007357
134 POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT 5 232 2.262e-05 0.0007856
135 REGULATION OF STEM CELL DIFFERENTIATION 4 113 2.364e-05 0.0008147
136 SENSORY ORGAN MORPHOGENESIS 5 239 2.609e-05 0.0008927
137 EMBRYONIC ORGAN DEVELOPMENT 6 406 2.65e-05 9e-04
138 COCHLEA DEVELOPMENT 3 39 2.684e-05 0.0009048
139 REGULATION OF NEURON PROJECTION DEVELOPMENT 6 408 2.724e-05 0.0009118
140 REGULATION OF ORGAN MORPHOGENESIS 5 242 2.77e-05 0.0009206
141 AORTA DEVELOPMENT 3 41 3.124e-05 0.00103
142 CENTRAL NERVOUS SYSTEM DEVELOPMENT 8 872 3.144e-05 0.00103
143 POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION 9 1152 3.216e-05 0.001047
144 KIDNEY EPITHELIUM DEVELOPMENT 4 125 3.514e-05 0.001135
145 NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION 3 43 3.609e-05 0.001158
146 NEGATIVE REGULATION OF CELL PROLIFERATION 7 643 3.669e-05 0.001169
147 MUSCLE STRUCTURE DEVELOPMENT 6 432 3.751e-05 0.001187
148 NEGATIVE REGULATION OF HEMOPOIESIS 4 128 3.856e-05 0.001212
149 NEGATIVE REGULATION OF GENE EXPRESSION 10 1493 3.917e-05 0.001223
150 REGULATION OF EPIDERMAL CELL DIFFERENTIATION 3 45 4.142e-05 0.001285
151 NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS 10 1517 4.492e-05 0.001384
152 POSITIVE REGULATION OF GLIOGENESIS 3 47 4.723e-05 0.001446
153 GLIAL CELL DIFFERENTIATION 4 136 4.887e-05 0.001486
154 CELL ACTIVATION INVOLVED IN IMMUNE RESPONSE 4 139 5.321e-05 0.001608
155 NEURON DEVELOPMENT 7 687 5.586e-05 0.001677
156 HEAD DEVELOPMENT 7 709 6.817e-05 0.002033
157 IMMUNE EFFECTOR PROCESS 6 486 7.218e-05 0.002139
158 UROGENITAL SYSTEM DEVELOPMENT 5 299 7.574e-05 0.00223
159 OUTFLOW TRACT MORPHOGENESIS 3 56 8.001e-05 0.002341
160 POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION 5 303 8.064e-05 0.002345
161 POSITIVE REGULATION OF NEURON DIFFERENTIATION 5 306 8.447e-05 0.002441
162 REGULATION OF GLIAL CELL DIFFERENTIATION 3 59 9.355e-05 0.002687
163 REGULATION OF HEMOPOIESIS 5 314 9.539e-05 0.002723
164 POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 4 162 9.645e-05 0.002736
165 EMBRYONIC DIGIT MORPHOGENESIS 3 61 0.0001034 0.002915
166 SOMITOGENESIS 3 62 0.0001085 0.003023
167 CARDIAC VENTRICLE MORPHOGENESIS 3 62 0.0001085 0.003023
168 REGULATION OF PROTEIN BINDING 4 168 0.000111 0.003074
169 REGULATION OF EPIDERMIS DEVELOPMENT 3 63 0.0001138 0.003097
170 APPENDAGE DEVELOPMENT 4 169 0.0001136 0.003097
171 LIMB DEVELOPMENT 4 169 0.0001136 0.003097
172 LOOP OF HENLE DEVELOPMENT 2 11 0.0001186 0.003154
173 NEGATIVE REGULATION OF SPROUTING ANGIOGENESIS 2 11 0.0001186 0.003154
174 NEGATIVE REGULATION OF GLIAL CELL PROLIFERATION 2 11 0.0001186 0.003154
175 REGULATION OF PROTEIN ACETYLATION 3 64 0.0001193 0.003154
176 VENTRICULAR TRABECULA MYOCARDIUM MORPHOGENESIS 2 11 0.0001186 0.003154
177 GLIOGENESIS 4 175 0.0001299 0.003416
178 FOREBRAIN GENERATION OF NEURONS 3 66 0.0001308 0.003418
179 REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION 5 337 0.0001329 0.003454
180 REGULATION OF DNA TEMPLATED TRANSCRIPTION IN RESPONSE TO STRESS 3 67 0.0001367 0.003535
181 AMYLOID PRECURSOR PROTEIN METABOLIC PROCESS 2 12 0.0001422 0.003597
182 DISTAL TUBULE DEVELOPMENT 2 12 0.0001422 0.003597
183 LATERAL VENTRICLE DEVELOPMENT 2 12 0.0001422 0.003597
184 POSITIVE REGULATION OF ASTROCYTE DIFFERENTIATION 2 12 0.0001422 0.003597
185 COVALENT CHROMATIN MODIFICATION 5 345 0.0001483 0.003721
186 REGULATION OF IMMUNE SYSTEM PROCESS 9 1403 0.0001487 0.003721
187 REGULATION OF CELL PROJECTION ORGANIZATION 6 558 0.000154 0.003833
188 REGULATION OF CYTOKINE PRODUCTION 6 563 0.0001617 0.003958
189 POSITIVE REGULATION OF CELL PROLIFERATION 7 814 0.0001615 0.003958
190 SKIN EPIDERMIS DEVELOPMENT 3 71 0.0001625 0.003958
191 CELL FATE SPECIFICATION 3 71 0.0001625 0.003958
192 NEURONAL STEM CELL DIVISION 2 13 0.0001679 0.003966
193 NEGATIVE REGULATION OF OLIGODENDROCYTE DIFFERENTIATION 2 13 0.0001679 0.003966
194 EPITHELIAL CELL DEVELOPMENT 4 186 0.0001643 0.003966
195 VASCULAR SMOOTH MUSCLE CELL DIFFERENTIATION 2 13 0.0001679 0.003966
196 LEFT RIGHT AXIS SPECIFICATION 2 13 0.0001679 0.003966
197 NEUROBLAST DIVISION 2 13 0.0001679 0.003966
198 POSITIVE REGULATION OF STAT CASCADE 3 73 0.0001765 0.004126
199 POSITIVE REGULATION OF JAK STAT CASCADE 3 73 0.0001765 0.004126
200 REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE 2 14 0.0001957 0.004531
201 BETA AMYLOID METABOLIC PROCESS 2 14 0.0001957 0.004531
202 POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS 8 1135 0.0002001 0.00459
203 CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION 5 368 0.0002003 0.00459
204 RESPIRATORY SYSTEM DEVELOPMENT 4 197 0.0002047 0.00467
205 REGULATION OF CELL DEATH 9 1472 0.0002142 0.004851
206 SOMITE DEVELOPMENT 3 78 0.0002148 0.004851
207 RESPONSE TO MURAMYL DIPEPTIDE 2 15 0.0002256 0.005047
208 REGULATION OF CELL PROLIFERATION INVOLVED IN HEART MORPHOGENESIS 2 15 0.0002256 0.005047
209 POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS 9 1492 0.0002372 0.00528
210 NEGATIVE REGULATION OF CELL DEATH 7 872 0.0002468 0.005467
211 POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION 7 876 0.0002538 0.005596
212 MORPHOGENESIS OF AN ENDOTHELIUM 2 16 0.0002576 0.005602
213 CARDIAC RIGHT VENTRICLE MORPHOGENESIS 2 16 0.0002576 0.005602
214 APOPTOTIC PROCESS INVOLVED IN MORPHOGENESIS 2 16 0.0002576 0.005602
215 REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION 4 213 0.0002758 0.005969
216 GLAND DEVELOPMENT 5 395 0.0002779 0.005986
217 REGULATION OF CHROMATIN BINDING 2 17 0.0002917 0.006226
218 MEMBRANE PROTEIN INTRACELLULAR DOMAIN PROTEOLYSIS 2 17 0.0002917 0.006226
219 TISSUE REMODELING 3 87 0.0002965 0.0063
220 CELLULAR COMPONENT MORPHOGENESIS 7 900 0.0002993 0.006331
221 SEGMENTATION 3 89 0.000317 0.006675
222 PERICARDIUM DEVELOPMENT 2 18 0.0003279 0.006841
223 REGULATION OF GLIOGENESIS 3 90 0.0003276 0.006841
224 TELENCEPHALON DEVELOPMENT 4 228 0.0003572 0.007419
225 REGULATION OF DNA BINDING 3 93 0.0003608 0.007461
226 REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS 4 229 0.0003631 0.007477
227 REGULATION OF CELL MIGRATION INVOLVED IN SPROUTING ANGIOGENESIS 2 19 0.0003661 0.007504
228 CANONICAL WNT SIGNALING PATHWAY 3 95 0.0003841 0.007838
229 CARDIOCYTE DIFFERENTIATION 3 96 0.0003961 0.008047
230 MEMORY 3 98 0.0004208 0.008475
231 POSITIVE REGULATION OF GROWTH 4 238 0.0004202 0.008475
232 LEFT RIGHT PATTERN FORMATION 2 21 0.0004487 0.008848
233 REGULATION OF GLIAL CELL PROLIFERATION 2 21 0.0004487 0.008848
234 APOPTOTIC PROCESS INVOLVED IN DEVELOPMENT 2 21 0.0004487 0.008848
235 COCHLEA MORPHOGENESIS 2 21 0.0004487 0.008848
236 POSITIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY 3 100 0.0004464 0.008848
237 BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY 2 22 0.0004932 0.009682
NumGOOverlapSizeP ValueAdj. P Value
1 NOTCH BINDING 8 18 4e-19 3.716e-16
2 TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING 10 588 7.904e-09 3.671e-06
3 RECEPTOR BINDING 13 1476 6.661e-08 2.063e-05
4 BETA CATENIN BINDING 5 84 1.52e-07 3.53e-05
5 TRANSCRIPTION COACTIVATOR ACTIVITY 7 296 2.203e-07 4.094e-05
6 TRANSCRIPTION FACTOR BINDING 8 524 7.412e-07 0.0001148
7 CALCIUM ION BINDING 8 697 6.194e-06 0.000822
8 CHROMATIN BINDING 6 435 3.899e-05 0.004528
NumGOOverlapSizeP ValueAdj. P Value
1 CHROMOSOME 8 880 3.357e-05 0.00565
2 APICAL PART OF CELL 6 361 1.366e-05 0.00565
3 CHROMATIN 6 441 4.209e-05 0.00565
4 NUCLEAR CHROMATIN 5 291 6.663e-05 0.00565
5 NUCLEOPLASM PART 7 708 6.756e-05 0.00565
6 GOLGI MEMBRANE 7 703 6.461e-05 0.00565
7 APICAL PLASMA MEMBRANE 5 292 6.772e-05 0.00565
8 WNT SIGNALOSOME 2 11 0.0001186 0.00866

Over-represented Pathway

NumPathwayPathviewOverlapSizeP ValueAdj. P Value
1 hsa04330_Notch_signaling_pathway 30 47 6.921e-85 1.246e-82
2 hsa04320_Dorso.ventral_axis_formation 4 25 5.089e-08 4.58e-06
3 hsa04310_Wnt_signaling_pathway 6 151 8.571e-08 5.143e-06
4 hsa04916_Melanogenesis 4 101 1.518e-05 0.000683
5 hsa04110_Cell_cycle 3 128 0.0009162 0.03298
6 hsa04720_Long.term_potentiation 2 70 0.004931 0.1376
7 hsa04520_Adherens_junction 2 73 0.00535 0.1376
8 hsa04350_TGF.beta_signaling_pathway 2 85 0.007188 0.1617
9 hsa04722_Neurotrophin_signaling_pathway 2 127 0.01549 0.3099
10 hsa04390_Hippo_signaling_pathway 2 154 0.02225 0.3686
11 hsa04630_Jak.STAT_signaling_pathway 2 155 0.02252 0.3686

lncRNA-mediated sponge

(Download full result)

Num lncRNA miRNAs           miRNAs count     Gene Sponge regulatory network lncRNA log2FC lncRNA pvalue Gene log2FC Gene pvalue lncRNA-gene Pearson correlation

Quest ID: 4430eff1aba0ab486d04c4a5daaa4143